Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.70997 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jung Sun Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Nivolumab, Ipilimumab, Carcinoma, Hepatocellular. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, considering prior ICI exposure, compared with nivolumab (Nivo) monotherapy.
Methods
We analyzed 204 lesions from Nivo/Ipi‐treated and 305 lesions from Nivo‐treated patients with advanced HCC at five referral cancer centers in Korea. Organ‐specific response criteria were adopted from Response Evaluation Criteria in Solid Tumors 1.1, according to the indicated sites: the liver, lung, lymph nodes (LNs), and other metastatic sites.
Results
Nivo/Ipi combination therapy showed OSORRs of 18.1% in the liver, 17.7% in the lungs, 30.0% in LNs, and 12.5% in other metastatic sites. Patients without prior ICI exposure had OSORRs of 29.0% in the liver, 31.3% in the lungs, 33.3% in LNs, and 23.1% in other metastatic sites (72 individual lesions). Conversely, patients with prior ICI exposure had OSORRs of 11.5% in the liver, 11.4% in the lung, 27.8% in LNs, and 7.4% in other metastatic sites (132 individual lesions). Furthermore, patients who achieved a response in the liver or the lung had longer progression‐free and overall survival, compared with those without responses. Nivo monotherapy yielded OSORRs of 13.5%, 25.3%, 39.3%, and 18.4% in the liver, lungs, LNs, and other metastatic sites, respectively.
Conclusion
Nivo/Ipi combination therapy induced superior intrahepatic responses compared to Nivo monotherapy in patients with advanced HCC without prior ICI exposure, highlighting its potential to overcome liver‐specific immune tolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
- CHA University School of Medicine, Seongnam, Korea.
- Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
- Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
ORCID-Profile: Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, J. S., Kim, Y., Kang, B., Kim, I., Kim, H., Lee, W. S., Hong, J. Y., Lim, H. Y., Kim, H. S., Kim, C. G., Jung, S., An, C., Kim, C., & Chon, H. J. (2025). Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.70997
Vancouver
Kim JS, Kim Y, Kang B, Kim I, Kim H, Lee WS, et al. Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study. Cancer Medicine. 2025. doi:10.1002/cam4.70997
BibTeX
@article{Kim2025,
author = {Kim, Jung Sun and Kim, Youngun and Kang, Beodeul and Kim, Ilhwan and Kim, Hyeyeong and Lee, Won Suk and Hong, Jung Yong and Lim, Ho Yeong and Kim, Han Sang and Kim, Chang Gon and Jung, Sanghoon and An, Chansik and Kim, Chan and Chon, Hong Jae},
title = {Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70997}
}
EUVIMED